Phase I, Double-Blind, Placebo-Controlled Dose Escalating Assessment of Potential Interactions Between Intravenous Cocaine and RPR 102681
This is a human laboratory clinical pharmacology study to assess potential interactions between intravenous (i.v.) cocaine and RPR 102681 administered in 3 escalating doses.
May 23, 2017
The primary objective of this study is to determine if there are significant interactions between RPR 102681 treatment concurrent with i.v. cocaine infusions of 0 and 40 mg by measuring adverse events and cardiovascular responses [heart rate (HR), blood pressure (BP), and electrocardiogram (ECG)].
Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.